Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

25.07.2017 | original article | Ausgabe 3-4/2018 Open Access

Wiener Medizinische Wochenschrift 3-4/2018

Early onset of efficacy in patients with functional and motility-related gastrointestinal disorders

A noninterventional study with Iberogast®

Wiener Medizinische Wochenschrift > Ausgabe 3-4/2018
Richard Raedsch, Dr. Bettina Vinson, Bertram Ottillinger, Gerald Holtmann


STW 5 (Iberogast®; Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany) contains nine plant extracts and possesses well-documented overall efficacy in functional gastrointestinal disorders (FGID). Little is known about the onset of symptom relief. Twenty-nine centers in Germany recruited 272 patients with established FGID. These patients were treated with STW 5 for approximately 3 weeks in this noninterventional study. Patients assessed the severity of their gastrointestinal complaints before and at defined times after the intake of STW 5 (10 cm visual analogue scale; VAS). Fifteen minutes after the first dose, the severity of gastrointestinal complaints had decreased by 1.4 cm (mean; initial mean: 5.2 of 10 cm). After 1 h, more than 90% of the maximum effect of 3.2 cm on the 10 cm VAS had been reached. Most patients with symptoms experienced a marked improvement within 5, 15 or 30 min of taking STW 5. Absolute improvements were larger in patients with more pronounced baseline complaints. Subgroups with upper (80% of the study population) and lower FGID (20%) did not present major differences. Neither did subgroups by age and duration of complaints. Treatment with STW 5 resulted in rapid improvement of symptoms.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 3-4/2018

Wiener Medizinische Wochenschrift 3-4/2018 Zur Ausgabe